Link opens in a new tab
opens in new window
![]()
Perspective
NextGen cell and gene therapy
Personalized precision medicine is here
Cell and gene therapy (CGT) brings the promise of personalized precision medicine to life. As with any innovative, disruptive technology, however, developers face challenges along several dimensions—manufacturing, regulation, and reimbursement, among them—to become broadly commercially viable. How can life sciences organizations address these challenges and continue to advance CGTs?
Deloitte’s CGT experience spans the value chain
Discover insights
Opens in new window
